Get the Stockscreener App
7.27
1.22%
-0.09
Regenxbio Inc stock is traded at $7.27, with a volume of 612.58K.
It is down -1.22% in the last 24 hours and down -3.96% over the past month.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$7.36
Open:
$7.48
24h Volume:
612.58K
Relative Volume:
0.55
Market Cap:
$360.19M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-1.3821
EPS:
-5.26
Net Cash Flow:
$-194.72M
1W Performance:
-0.41%
1M Performance:
-3.96%
6M Performance:
-40.46%
1Y Performance:
-60.49%
1-Day Range:
$7.22
$7.56
1-Week Range:
$7.22
$7.79
52-Week Range:
$6.56
$28.80
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
7.27 | 360.19M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-07-25 | Resumed | Raymond James | Outperform |
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Learn to Evaluate (RGNX) using the Charts - Stock Traders Daily
Goldman Sachs cuts Regenxbio stock rating, slashes price target - MSN
REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by SG Americas Securities LLC - Defense World
REGENXBIO (NASDAQ:RGNX) Lowered to Sell Rating by StockNews.com - Defense World
REGENXBIO (NASDAQ:RGNX) Downgraded to Neutral Rating by The Goldman Sachs Group - MarketBeat
Raymond James Upgrades REGENXBIO (NASDAQ:RGNX) to Moderate Buy - MarketBeat
Goldman Sachs cuts Regenxbio stock rating, slashes price target By Investing.com - Investing.com Australia
Raymond James Begins Coverage on REGENXBIO (NASDAQ:RGNX) - MarketBeat
Goldman Sachs Downgrades REGENXBIO (RGNX) - MSN
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns - Benzinga
Regenxbio Shares Fall After Downgrade From Goldman Sachs -February 11, 2025 at 02:53 pm EST - Marketscreener.com
Wall Street Analysts Think Regenxbio (RGNX) Could Surge 333.01%: Read This Before Placing a Bet - MSN
Goldman Sachs Downgrades REGENXBIO to Neutral From Buy, Cuts Price Target to $14 From $38 - Marketscreener.com
A Glimpse Into The Expert Outlook On Regenxbio Through 7 Analysts - Benzinga
REGENXBIO (NASDAQ:RGNX) Research Coverage Started at Raymond James - Defense World
REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at StockNews.com - MarketBeat
How To Trade (RGNX) - Stock Traders Daily
Analysts Set REGENXBIO Inc. (NASDAQ:RGNX) PT at $34.82 - Armenian Reporter
Raymond James sets $27 target for Regenxbio stock - MSN
The Potential Rise in the Price of Regenxbio Inc (RGNX) following insiders activity - Knox Daily
STATE STREET CORP Reduces Stake in Regenxbio Inc: An In-Depth Analysis - GuruFocus.com
Are Regenxbio Inc (RGNX) shares a good deal now? - US Post News
Investors in REGENXBIO (NASDAQ:RGNX) from five years ago are still down 84%, even after 11% gain this past week - Simply Wall St
Analyzing Ratios: Regenxbio Inc (RGNX)’s Financial Story Unveiled - The Dwinnex
With 71% ownership of the shares, REGENXBIO Inc. (NASDAQ:RGNX) is heavily dominated by institutional owners - Yahoo Finance
FY2026 EPS Estimates for REGENXBIO Lifted by Leerink Partnrs - Defense World
Vanguard Group Inc Reduces Stake in Regenxbio Inc - GuruFocus.com
REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025 - PR Newswire
Objective long/short (RGNX) Report - Stock Traders Daily
REGENXBIO, Inc. to Host Earnings Call - ACCESS Newswire
Wall Street Analysts See a 357.36% Upside in Regenxbio (RGNX): Can the Stock Really Move This High? - MSN
FY2024 EPS Estimates for REGENXBIO Lifted by Leerink Partnrs - Defense World
Leerink Partnrs Increases Earnings Estimates for REGENXBIO - MarketBeat
Analysts Offer Predictions for REGENXBIO FY2029 Earnings - MarketBeat
REGENXBIO’s (RGNX) Outperform Rating Reaffirmed at Royal Bank of Canada - Defense World
REGENXBIO's (RGNX) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
$810 Million Turned Into a Rare Disease Revolution with Japan’s Nippon Shinyaku’s and USA’s REGENXBIO’s Partnership - geneonline
Assenagon Asset Management S.A. Purchases 296,700 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
Assenagon Asset Management S.A. Has $6.62 Million Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Regenxbio and Nippon Shinyaku forge $810m gene therapy deal - MSN
(RGNX) Technical Data - Stock Traders Daily
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Regenxbio Inc Stock (RGNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KARABELAS ARGERIS N | Director |
Oct 01 '24 |
Option Exercise |
3.76 |
10,000 |
37,600 |
21,286 |
| KARABELAS ARGERIS N | Director |
Oct 01 '24 |
Sale |
10.11 |
10,000 |
101,052 |
11,286 |
| KARABELAS ARGERIS N | Director |
Sep 03 '24 |
Option Exercise |
3.76 |
10,000 |
37,600 |
21,286 |
| KARABELAS ARGERIS N | Director |
Sep 03 '24 |
Sale |
11.56 |
10,000 |
115,588 |
11,286 |
| Mills Kenneth T. | Director |
Aug 08 '24 |
Option Exercise |
0.85 |
36,316 |
30,869 |
444,351 |
| KARABELAS ARGERIS N | Director |
Aug 01 '24 |
Option Exercise |
3.85 |
10,100 |
38,874 |
21,386 |
| KARABELAS ARGERIS N | Director |
Aug 01 '24 |
Sale |
13.51 |
10,100 |
136,454 |
11,286 |
| Simpson Curran | Chief Executive Officer |
Aug 01 '24 |
Sale |
15.00 |
100 |
1,500 |
170,037 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):